|
GPR107 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.46380019216963E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.31910002102387E-09 |
| Normal-vs-Stage2 |
1.077030E-03 |
| Normal-vs-Stage3 |
8.21199996892119E-10 |
| Normal-vs-Stage4 |
8.97359997420466E-09 |
| Stage1-vs-Stage2 |
3.628400E-01 |
| Stage1-vs-Stage3 |
2.761200E-01 |
| Stage1-vs-Stage4 |
9.318100E-02 |
| Stage2-vs-Stage3 |
1.591550E-01 |
| Stage2-vs-Stage4 |
7.567600E-02 |
| Stage3-vs-Stage4 |
5.203400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.19759979710921E-10 |
| Normal-vs-AfricanAmerican |
6.578900E-03 |
| Normal-vs-Asian |
8.57449999891458E-08 |
| Caucasian-vs-AfricanAmerican |
2.001400E-01 |
| Caucasian-vs-Asian |
6.197200E-01 |
| AfricanAmerican-vs-Asian |
1.131800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.98080000179957E-08 |
| Normal-vs-Female |
4.73500016973105E-10 |
| Male-vs-Female |
5.888800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.07160000159834E-08 |
| Normal-vs-Age(41-60Yrs) |
1.32499999860869E-08 |
| Normal-vs-Age(61-80Yrs) |
3.830500028279E-09 |
| Normal-vs-Age(81-100Yrs) |
6.401100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.296400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.266400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.909600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.382400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.398200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.866000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.791900E-02 |
| Classical-VS-Follicular |
9.313000E-01 |
| Classical-VS-Other |
6.360200E-02 |
| Classical-VS-Normal |
2.81659995327033E-09 |
| Tall-VS-Follicular |
3.037700E-02 |
| Tall-VS-Other |
3.973800E-01 |
| Tall-VS-Normal |
5.26440002701634E-09 |
| Follicular-VS-Other |
1.307200E-01 |
| Follicular-VS-Normal |
2.45089999999504E-05 |
| Other-VS-Normal |
3.220400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.85249999573989E-08 |
| Normal-vs-N1 |
4.24530000042722E-09 |
| N0-vs-N1 |
2.571800E-02 |
|
|
